Annals of Oncology
Publisher: Elsevier · ISSN 0923-7534 · 64 articles
-
A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer☆
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): M. Cecchini, M. Cruz-Correa, S.-W. Han, K. Raghav, A. Landa-Magdalena, J.H. Strickler, A. Calvo, A. Hollebecque, T.E. Nakajima, G. Perl, V. Jain,...
-
Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW☆
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): S. Lonardi, H.-J. Lenz, E. Elez, L.H. Jensen, E. Van Cutsem, Y. Touchefeu, R. Garcia-Carbonero, D. Tougeron, G.A. Mendez, M. Schenker, C. de la...
-
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study
Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): Brian I. Rini, Toni K. Choueiri, Martin H. Voss, Mauricio Burotto, Jan Oldenburg, Howard P. Gurney, Thomas R. Ferguson, Hans Hammers, Laurence...
-
Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy☆
Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): D.Y.C. Heng, M. Schmidinger, R. McDermott, S.H. Park, M. Burotto, C. Ciccarese, E. Verzoni, C. Suárez, M. Eto, H.J. Cutuli, C. Porta, R. Manneh...
-
Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial
Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): Andrea Cercek, Jean-Baptiste Bachet, Gunnar Folprecht, Hideaki Bando, Jenny Seligmann, Naureen Starling, Maria Carmen Riesco-Martinez, Pilar Garcia...
-
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020)
Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): Renaud Descourt, Alice Mogenet, Maelys Consigny, Marie Bernardi, Romain Corre, Olivier Bylicki, Jean-Bernard Auliac, Alain Vergnenègre, Charles...
-
From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology’s New Pillar
Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): Ken Herrmann
-
A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study☆
Publication date: Available online 25 October 2026 Source: Annals of Oncology Author(s): J. Bennouna, T. André, E. Martin, C. Cremolini, S. Gill, T. Asmis, P. Kavan, E. Mitry, S. Hiret, L. Mineur, P. Artru, C. Perret, O. Bouché, Y....
-
Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial☆
Publication date: Available online 26 October 2026 Source: Annals of Oncology Author(s): L. Xie, W. Yao, Y. Hua, W. Luo, C. Tu, J. Wang, J. Chen, B. Li, D. Zhu, X. Li, Y. Xiao, J. Ma, H. Hu, M. Fang, Z. Huang, H. Wang, Q. Liu, Y. Jin,...
-
Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01
Publication date: Available online 26 October 2026 Source: Annals of Oncology Author(s): B. Xu, Y. Yin, Y. Fan, Q. Ouyang, L. Song, X. Wang, W. Li, M. Li, X. Yan, S. Wang, T. Sun, Y. Teng, X. Tang, Z. Tong, Z. Sun, G. Liu, Y. Diao, X. Jin, J. Ge
-
Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase III DeLLphi-304 study☆
Publication date: Available online 26 October 2026 Source: Annals of Oncology Author(s): C.M. Rudin, M.-J. Ahn, M. Schuler, F.H. Blackhall, G. Mountzios, T. Yoshida, L. Sun, B.C. Cho, A. Lugini, S. Arulananda, S.R. Punekar, P. Rocha, L....
-
Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer ☆
Publication date: Available online 26 October 2026 Source: Annals of Oncology Author(s): Z.M. Li, L. Wu, W.X. Wang, L.H. Sun, P. Zhang, W.T. Fang, Y. Zheng, Q.X. Chen, L. Yang, L.J. Tan, J.D. Mei, J.L. Shan, S.D. Xu, X.H. Sun, N. Yang,...
-
CheckMate 8HW: one checkmate, several moves left
Publication date: Available online 27 October 2026 Source: Annals of Oncology Author(s): J. Taieb
-
Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study
Publication date: Available online 27 October 2026 Source: Annals of Oncology Author(s): N. Cunningham, C. Swift, R.J. Cutts, K. Thomas, S.Sardo Infirri, F. Dalenc, F. Le Du, I.R. Macpherson, C. O’Brien, C. Palmieri, P. Schmid, F....
-
Table of Contents
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s):
-
Editorial Board
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s):
-
Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): L. Arecco, M. Lambertini
-
SKYSCRAPER-07: falling short of the top
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): S.S. Kim, N.V. Uboha
-
Long-term benefit from immune checkpoint inhibition in squamous esophageal cancer
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): V.E. Blanco, E. Smyth
-
TIGIT at a crossroads: lessons from SKYSCRAPER-03 in unresectable stage III NSCLC
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): Y. Zenke
-
ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): T. Conroy, M. Ducreux, ESMO Guidelines Committee
-
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): J.E. Garber, D. Cameron, C. Campbell, G. Yothers, M. Taboada, S. El-Abed, P. Rastogi, R. McConnell, A. Correa, S. Delaloge, W.T. Liu, P. Sharma,...
-
Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study☆
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): J. Zhang, Y. Meng, Y. Du, T. Sun, J. Cui, Y. Chen, Y. Sun, Y. Wang, W. Chen, F. Xu, Y. Shi, Y. Chen, K. Wang, G. Jin, H. Zhou, Z. Zhuang, W. Xie,...
-
Atezolizumab with or without tiragolumab in unresectable esophageal squamous-cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): R.H. Xu, B.C. Cho, M. Chen, K. Muro, L. Wyrwicz, B. Li, S. Gao, C. Hsu, A. Turpin, F. Lordick, E. Cha, Q. Wu, S. Kim, J. Cai, L. Zhang, J. Fan,...
-
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): K. Kato, J. Ajani, Y. Doki, J. Xu, L. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, C.-H. Hsu, A. Adenis, F. el Hajbi, M. Di Bartolomeo, M. Ignez...
-
SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation☆
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): H.A. Wakelee, M.-J. Ahn, J. Bradley, S. Popat, K. Kelly, A.-M. Baird, O. Ozyilkan, J. Yu, S.Y. Lee, N. Yanagitani, M. Johnson, A....
-
Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): H. Wakelee, J.D. Spicer, S. Gao, M. Liberman, M. Tsuboi, T. Kato, K.-N. Chen, C. Dooms, M. Majem, G.L. Martinengo, O. Bylicki, D....
-
Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): A.Y. Zhang, H. Thomas, S. Begbie, L. Cheung, K.N. Chi, S. Chowdhury, M. Frydenberg, C. Herberstein, L.G. Horvath, A.M. Joshua, N.J. Lawrence, G....
-
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): F. Facchinetti, L. Friboulet, L. Liao, M. Peroni, S. Nakazawa, L. Zullo, M. Aldea, F. Pecci, M. Makarem, I. Alonso Garcia, R. Minari, B....
-
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study☆
Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): N.B. Haas, T.B. Powles, P. Tomczak, S.H. Park, B. Venugopal, S.N. Symeonides, T. Ferguson, Y.-H. Chang, J.-L. Lee, P. Sawrycki, N. Sarwar, H....